Claims
- 1. A multi-arm block copolymer useful as a drug delivery vehicle, comprising:
a central core molecule comprising a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, at least one of the hydrophobic and hydrophilic polymer segments comprising at least one degradable linkage, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region.
- 2. The multi-arm block copolymer of claim 1, wherein the central core molecule is a residue of a polyol selected from the group consisting of glycerol, sorbitol, pentaerythritol, and glycerol oligomers.
- 3. The multi-arm block copolymer of claim 1, wherein the central core molecule is a residue of hexaglycerol.
- 4. The multi-arm block copolymer of claim 1, wherein the central core molecule is a residue of hydroxypropyl-β-cyclodextrin.
- 5. The multi-arm block copolymer of claim 1, wherein the inner hydrophobic polymer segment is selected from the group consisting of a poly(hydroxyester), a poly(alkylene oxide) other than poly(ethylene glycol), or a copolymer thereof.
- 6. The multi-arm block copolymer of claim 1, wherein the inner hydrophobic polymer segment is poly(propylene glycol).
- 7. The multi-arm block copolymer of claim 1, wherein the inner hydrophobic polymer segment is a poly(hydroxyester) selected from the group consisting of poly(lactide), poly(glycolide), poly(lactide)/(glycolide) copolymer, poly(butyrolactide), and polycaprolactone.
- 8. The multi-arm block copolymer of claim 1, wherein the outer hydrophilic polymer segment comprises poly(ethylene glycol).
- 9. The multi-arm block copolymer of claim 1, wherein each hydrophobic and hydrophilic polymer segment has a molecular weight of about 500 Da to about 100,000 Da.
- 10. The multi-arm block copolymer of claim 1, wherein the hydrophobic polymer segment has a molecular weight of about 10,000 Da to about 40,000 Da.
- 11. The multi-arm block copolymer of claim 1, wherein the hydrophilic polymer segment has a molecular weight of about 1,000 Da to about 20,000 Da.
- 12. The multi-arm block copolymer of claim 1, wherein the central core molecule is attached to at least 5 copolymer arms.
- 13. The multi-arm block copolymer of claim 1, wherein the central core molecule is attached to at least 8 copolymer arms.
- 14. The multi-arm block copolymer of claim 1, wherein the central core molecule is attached to at least 10 copolymer arms.
- 15. The multi-arm block copolymer of claim 1, wherein at least one targeting moiety is covalently attached to at least one hydrophilic polymer segment.
- 16. The multi-arm block copolymer of claim 15, wherein the targeting moiety is a bisphosphonate.
- 17. The multi-arm block copolymer of claim 1, wherein at least one capping group is covalently attached to at least one hydrophilic polymer segment.
- 18. The multi-arm block copolymer of claim 17, wherein the capping group is selected from the group consisting of alkoxy, hydroxyl, protected hydroxyl, active ester, active carbonate, acetal, aldehyde, aldehyde hydrates, alkyl or aryl sulfonate, halide, disulfide, alkenyl, acrylate, methacrylate, acrylamide, active sulfone, amine, protected amine, hydrazide, protected hydrazide, thiol, protected thiol, carboxylic acid, protected carboxylic acid, isocyanate, isothiocyanate, maleimide, vinylsulfone, dithiopyridine, vinylpyridine, iodoacetamide, epoxide, glyoxals, diones, mesylates, tosylates, or tresylate.
- 19. The multi-arm block copolymer of claim 1, having the structure:
- 20. The multi-arm block copolymer of claim 19, wherein each D is alkoxy.
- 21. The multi-arm block copolymer of claim 19, wherein each D is hydroxy.
- 22. The multi-arm block copolymer of claim 19, wherein each D is selected from the group consisting of alkoxy, hydroxyl, protected hydroxyl, active ester, active carbonate, acetal, aldehyde, aldehyde hydrates, alkyl or aryl sulfonate, halide, disulfide, alkenyl, acrylate, methacrylate, acrylamide, active sulfone, amine, protected amine, hydrazide, protected hydrazide, thiol, protected thiol, carboxylic acid, protected carboxylic acid, isocyanate, isothiocyanate, maleimide, vinylsulfone, dithiopyridine, vinylpyridine, iodoacetamide, epoxide, glyoxals, diones, mesylates, tosylates, or tresylate.
- 23. The multi-arm block copolymer of claim 19, wherein A is a residue of a polyol selected from the group consisting of glycerol, sorbitol, pentaerythritol, hydroxypropyl-β-cyclodextrin, and glycerol oligomers.
- 24. The multi-arm block copolymer of claim 19, wherein B is selected from the group consisting of a poly(hydroxyester), a poly(alkylene oxide) other than poly(ethylene glycol), or a copolymer thereof.
- 25. The multi-arm block copolymer of claim 19, wherein B is poly(propylene oxide).
- 26. The multi-arm block copolymer of claim 19, wherein B is a poly(hydroxyester) selected from the group consisting of poly(lactide), poly(glycolide), poly(lactide)/(glycolide) copolymer, poly(butyrolactide), and polycaprolactone.
- 27. The multi-arm block copolymer of claim 19, wherein at least one of B and C comprises at least one degradable linkage.
- 28. The multi-arm block copolymer of claim 19, wherein C comprises poly(ethylene glycol).
- 29. The multi-arm block copolymer of claim 19, wherein C comprises a hydrolyzable linkage selected from the group consisting of esters, carbonates, imines, hydrazone, phosphate esters, orthoesters, peptides, or acetals.
- 30. The multi-arm block copolymer of claim 1, having the structure:
- 31. The multi-arm block copolymer of claim 1, having the structure:
- 32. The multi-arm block copolymer of claim 31, wherein T is selected from the group consisting of a protein, an antibody, an antibody fragment, a peptide, a carbohydrate, a lipid, an oligonucleotide, DNA, RNA, and a small molecule having molecular weight less than 2000 Daltons.
- 33. The multi-arm block copolymer of claim 31, wherein T is a bisphosphonate.
- 34. A multi-arm block copolymer useful as a drug delivery vehicle, comprising:
a central core molecule comprising a residue of a polyol, and at least five copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region.
- 35. The multi-arm block copolymer of claim 34, wherein the central core molecule is a residue of a polyol selected from the group consisting of glycerol, sorbitol, pentaerythritol, and glycerol oligomers.
- 36. The multi-arm block copolymer of claim 34, wherein the inner hydrophobic polymer segment is selected from the group consisting of a poly(hydroxyester), a poly(alkylene oxide) other than poly(ethylene glycol), or a copolymer thereof.
- 37. The multi-arm block copolymer of claim 34, wherein the inner hydrophobic polymer segment is a poly(hydroxyester) selected from the group consisting of poly(lactide), poly(glycolide), poly(lactide)/(glycolide) copolymer, and polycaprolactone.
- 38. The multi-arm block copolymer of claim 34, wherein at least one of the inner hydrophobic polymer segment and the outer hydrophilic polymer segment comprises at least one degradable linkage.
- 39. The multi-arm block copolymer of claim 34, wherein the outer hydrophilic polymer segment comprises poly(ethylene glycol).
- 40. The multi-arm block copolymer of claim 34, wherein the central core molecule is attached to at least 8 copolymer arms.
- 41. The multi-arm block copolymer of claim 34, wherein the central core molecule is attached to at least 10 copolymer arms.
- 42. The multi-arm block copolymer of claim 34, wherein at least one targeting moiety is covalently attached to at least one hydrophilic polymer segment.
- 43. The multi-arm block copolymer of claim 42, wherein the targeting moiety is a bisphosphonate.
- 44. The multi-arm block copolymer of claim 34, wherein at least one capping group is covalently attached to at least one hydrophilic polymer segment.
- 45. The multi-arm block copolymer of claim 44, wherein the capping group is selected from the group consisting of alkoxy, hydroxyl, protected hydroxyl, active ester, active carbonate, acetal, aldehyde, aldehyde hydrates, alkyl or aryl sulfonate, halide, disulfide, alkenyl, acrylate, methacrylate, acrylamide, active sulfone, amine, protected amine, hydrazide, protected hydrazide, thiol, protected thiol, carboxylic acid, protected carboxylic acid, isocyanate, isothiocyanate, maleimide, vinylsulfone, dithiopyridine, vinylpyridine, iodoacetamide, epoxide, glyoxals, diones, mesylates, tosylates, or tresylate.
- 46. A pharmaceutical composition, comprising:
a multi-arm block copolymer, the block copolymer comprising a central core molecule comprising a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region, and at least one biologically active agent entrapped within the hydrophobic core region of the multi-arm block copolymer.
- 47. The pharmaceutical composition of claim 46, wherein the biologically active agent is selected from the group consisting of 3,4-di-[1-methyl 6-nitro-3-indolyl]-1H-pyrrole-2,5-dione (MNIPD), simvastatin, indomethacin, pivaloyloxymethyl butyrate, cyclosporin A, paclitaxel, analogs thereof, and pharmaceutically acceptable salts thereof.
- 48. The pharmaceutical composition of claim 46, wherein the central core molecule is a residue of a polyol selected from the group consisting of glycerol, sorbitol, pentaerythritol, hydroxypropyl-β-cyclodextrin, and glycerol oligomers.
- 49. The pharmaceutical composition of claim 46, wherein the inner hydrophobic polymer segment is selected from the group consisting of a poly(hydroxyester), a poly(alkylene oxide) other than poly(ethylene glycol), or a copolymer thereof.
- 50. The pharmaceutical composition of claim 46, wherein the inner hydrophobic polymer segment is poly(propylene glycol).
- 51. The pharmaceutical composition of claim 46, wherein the inner hydrophobic polymer segment is a poly(hydroxyester) selected from the group consisting of poly(lactide), poly(glycolide), poly(lactide)/(glycolide) copolymer, poly(butyrolactide), and polycaprolactone.
- 52. The pharmaceutical composition of claim 46, wherein at least one of the inner hydrophobic polymer segment and the outer hydrophilic polymer segment comprises at least one degradable linkage.
- 53. The pharmaceutical composition of claim 46, wherein the outer hydrophilic polymer segment comprises poly(ethylene glycol).
- 54. The pharmaceutical composition of claim 46, wherein each hydrophobic and hydrophilic polymer segment has a molecular weight of about 500 Da to about 100,000 Da.
- 55. The pharmaceutical composition of claim 46, wherein the hydrophobic polymer segment has a molecular weight of about 10,000 Da to about 40,000 Da.
- 56. The pharmaceutical composition of claim 46, wherein the hydrophilic polymer segment has a molecular weight of about 1,000 Da to about 20,000 Da.
- 57. The pharmaceutical composition of claim 46, wherein the central core molecule is attached to at least 5 copolymer arms.
- 58. The pharmaceutical composition of claim 46, wherein the central core molecule is attached to at least 8 copolymer arms.
- 59. The pharmaceutical composition of claim 46, wherein at least one targeting moiety is covalently attached to at least one hydrophilic polymer segment.
- 60. A method of preparing a pharmaceutical composition, comprising:
providing a multi-arm block copolymer, the block copolymer comprising a central core molecule comprising a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region, and entrapping a biologically active agent within the hydrophobic core region of the multi-arm block copolymer.
- 61. The method of claim 60, wherein said entrapping step comprises dissolving the multi-arm block copolymer and biologically active agent in an organic solvent to form a mixture and drying the mixture to form a solid pharmaceutical composition.
- 62. The method of claim 60, wherein said entrapping step comprises suspending the biologically active agent in an aqueous solution of the multi-arm block copolymer and subjecting the solution to ultrasonication.
- 63. The method of claim 60, wherein said entrapping step comprises mixing the biologically active agent and multi-arm block copolymer in solid form, heating the mixture to form a melt, and stirring the mixture to intimately mix the biologically active moiety and the multi-arm block copolymer.
- 64. A method of delivering a biologically active agent to a mammal, comprising:
administering a therapeutically effective amount of a pharmaceutical composition to the mammal, the pharmaceutical composition comprising:
a multi-arm block copolymer, the block copolymer comprising a central core molecule comprising a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region, and at least one biologically active agent entrapped within the hydrophobic core region of the multi-arm block copolymer.
- 65. The method of claim 64, wherein the biologically active agent is selected from the group consisting of 3,4-di-[1-methyl 6-nitro-3-indolyl]-1H-pyrrole-2,5-dione (MNIPD), simvastatin, indomethacin, , pivaloyloxymethyl butyrate, cyclosporin A, paclitaxel, analogs thereof, and pharmaceutically acceptable salts thereof.
- 66. The method of claim 64, wherein said administering step comprises administering by oral, buccal, rectal, topical, nasal, ophthalmic, parenteral, or inhalation routes.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of Provisional Application Serial No. 60/262,754, filed Jan. 19, 2001, which is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60262754 |
Jan 2001 |
US |